- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07946848
Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: IMM1104-201 Study Team
- 전화번호: (860) 321-1302
- 이메일: clinicaltrials@immuneering.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged 18 years or older
- Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
- Measurable disease (at least 1 target lesion) per RECIST 1.1.
- ECOG performance status of 0 or 1.
- PD-L1 score determined by an FDA-approved test.
- RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is acceptable.
- Adequate organ function:
Exclusion Criteria:
- Inability to swallow oral medications.
- EGFR, ALK or ROS1 mutation.
- Untreated or unresolved brain metastases
- Encephalitis, meningitis or uncontrolled seizures in the year before informed consent.
- History of interstitial lung disease non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids, or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
- Active autoimmune disease that required systemic treatment in the past 12 months.
- A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
- Prior allogeneic tissue or solid organ transplant.
- Never-smoker (fewer than 100 cigarettes in a lifetime).
- Prior anti-PD-1 or anti-PD-L1 therapy.
- Impaired cardiac function or clinically significant cardiac disease, including left ventricular ejection fraction <50% by ECHO or MUGA or screening QTcF >470 msec.
- History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
- History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
- Rhabdomyolysis within 3 months before Study Day 1.
- Major surgery or significant traumatic injury within 4 weeks before the first dose.
- Another malignancy.
- Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
- Uncontrolled HIV, hepatitis B or hepatitis C infection; immunodeficiency; or active or latent tuberculosis.
- Live vaccine within 4 weeks before the first dose.
- COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
- Known hypersensitivity to any study drug or excipient.
- Unwillingness to use effective contraception
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Atebimetinib + Cemiplimab ± Chemotherapy
Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 <50%. The expansion uses the atebimetinib dose selected during dose optimization. |
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
다른 이름들:
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
다른 이름들:
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4 500 mg/m² IV on Day 1 of Cycles 1-4
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib
기간: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
Measured in dose optimization |
Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
|
Objective Response Rate (ORR)
기간: Every 8 weeks, up to approximately 24 months
|
Percentage of participants with complete or partial response per RECIST 1.1 |
Every 8 weeks, up to approximately 24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Median Progression-Free Survival (PFS)
기간: Up to approximately 24 months.
|
Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first. |
Up to approximately 24 months.
|
|
Overall Survival (OS)
기간: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
Time from Cycle 1 Day 1 to death from any cause. |
From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
|
Number of Participants with adverse events
기간: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Treatment-emergent and treatment-related AEs per CTCAE v6.0 |
From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Vinny Hayreh, Immuneering Corporation
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- IMM1104-201
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .